uploads///Remodulin

An Update on United Therapeutics’ Remodulin, Tyvaso, and Unituxin

By

Updated

Remodulin’s revenue trends

In 4Q17, United Therapeutics’ (UTHR) Remodulin reported revenues of $180.1 million, up from $151.2 million in 4Q16. These revenues reflected ~19.0% growth on a year-over-year (or YoY) basis and an ~4.0% decline quarter-over-quarter.

In fiscal 2017, Remodulin reported revenues of $670.9 million, up from $602.3 million in 2016, which reflected ~11.4% YoY growth. Remodulin (treprostinil) injections are used for the treatment of individuals with pulmonary arterial hypertension (or PAH) for decreasing the symptoms associated with exercise.

Article continues below advertisement

Tyvaso’s revenue trends

In 4Q17, Tyvaso generated revenues of $92.4 million compared to $93.6 million in 4Q16, which reflected an ~1.0% decline on a YoY basis and 4.0% growth quarter-over-quarter.

In fiscal 2017, Tyvaso generated revenues of $372.9 million, down from $404.6 million in 2016, which reflected an ~7.8% decline on a YoY basis. Tyvaso (treprostinil) inhalation solution is used for the treatment of PAH for the improvement of exercise ability.

In the PAH drug market, United Therapeutics’ (UTHR) PAH portfolio competes with Actelion Pharmaceuticals’ Ventavis and Uptravi, Pfizer’s Revatio, and Gilead Sciences’ Letairis.

In June 2017, Johnson & Johnson (JNJ) acquired Actelion Pharmaceuticals. In 4Q17, Gilead Sciences’ (GILD) Letairis and Pfizer’s (PFE) Revatio reported revenues of $233.0 million and $62.0 million, respectively.

Unituxin’s revenue trends

In 4Q17, Unituxin generated revenues of $24.9 million for ~89.0% growth on a YoY basis and 46.0% growth on a quarter-over-quarter basis. In fiscal 2017, Unituxin reported revenues of $76.0 million, up from $62.5 million in 2016, which reflected ~21.6% growth on a YoY basis.

According to United Therapeutics’ prescribing information as approved by the FDA, “Unituxin (dinutuximab) is indicated in combination with granulocyte-macrophage colony-stimulating factor, interleukin-2 and 13-cis-retinoic acid for the treatment of pediatric individuals with high-risk neuroblastoma a who achieve at least a partial response to prior first-line multiagent, multimodality therapy.”

To learn more about Unituxin’s dosage, drug interactions, and adverse reactions, please refer to Unituxin’s prescribing information.

Advertisement

More From Market Realist